Estee Lantos Launches Refined Masterclass to Help People Slow Biological Aging by Transforming Stress from Within
Learn how nervous system regulation and optimised, yet not rigid lifestyle practices such as sleep, nourishment, movement can help you feel your best and slow down ageing, beginning June 1st
You're reading Entrepreneur United Kingdom, an international franchise of Entrepreneur Media.
Estee Lantos, a respected voice in biohacking and holistic wellness, is proud to unveil the revamped version of her "Biohack with Nervous System-first Masterclass – a transformative experience designed to help participants understand the factors that influence their biological age and how they can respond to life with more ease & connection. The masterclass is available online from June 1st and is priced at just £50.
This 90-minute pre-recorded training is a powerful entry point into Estee's broader wellness ecosystem, offering education and practical tools to to help people feel better, function optimally, and maintain youthful vitality.
Estee Lantos
"Our culture teaches us to manage stress after it happens. But what if you could train your body to respond differently in the first place?" says Estee. "The key to longevity isn't just in what you eat or how you sleep—it lies in a holistic approach that begins with how effectively you can guide your nervous system back to safety, and live from a place of ease.
Inside the Masterclass: A Step-by-Step Guide to Real Change
Participants will learn:
The science of stress and how the nervous system responds How to create safety within the body through cues and awareness Lifestyle pillars including sleep and recovery, cycle aligned movement and nourishment, cellular health and some other health optimisation practices that actually nourish you. A softer, more sustainable approach to wellness – focused on connection and community
But the masterclass is just the beginning. Estee offers a range of transformational services to support individuals at every stage of their wellness journey. Her practice is built around two other core offerings:
Somatic Work
Personalized support through 1:1 sessions online or in-person sessions, where clients are guided through TRE (Tension, Stress & Trauma Release Exercise) – a body-based practice to release stored stress and reset the nervous system. Ideal for those needing deeper emotional and physical grounding. The Path: 6-Month Transformational Program
Estee's signature, high-touch program that includes personalized biological age testing (in partnership with GlycanAge), customized plans, holistic protocols, and continuous coaching. It's an intimate experience built around accountability, deep change, and long-term vitality.
Why It Matters
Today, many people assume they are living healthy lives – but when they take a biological age test, they're shocked to discover their body is aging faster than expected. Estee's mission is to close this gap through a gentle, scientific, and highly personalised approach. The masterclass not only educates but empowers people to take back control of their health & longevity.
The Refined Masterclass is now live.
To learn more and join the experience, visit Estee's website or follow her on Instagram
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine
Data presented simultaneously at the American Diabetes Association's® 85th Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing weight loss interventions1 When adhering to treatment, weight loss of ≥5%, ≥20%, ≥25%, and ≥30% was observed in 97.6%, 60.2%, 40.4% and 23.1% of patients respectively at 68 weeks1* The REDEFINE clinical programme is ongoing to further investigate efficacy and safety of CagriSema, including recently initiated REDEFINE 112 Bagsværd, Denmark, 22 June – Today, The New England Journal of Medicine (NEJM) published results from Novo Nordisk's phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical complication and without diabetes.1 REDEFINE 1 met its co-primary endpoints and achieved statistically significant and clinically meaningful weight loss at 68 weeks in patients taking CagriSema versus placebo.1 These data, along with the related phase 3 REDEFINE 2 study conducted in adults with overweight or obesity and type 2 diabetes, were presented today during a scientific symposium at the American Diabetes Association's (ADA) 85th Scientific Sessions and published in NEJM. 'In REDEFINE 1, participants saw significant and clinically meaningful weight loss under a protocol that allowed investigators to maintain patients on a submaximal dose if deemed best for the patient. We also witnessed low, single-digit discontinuation rates due to adverse events in both REDEFINE 1 and 2,' said Martin Holst Lange, executive vice president and head of Development at Novo Nordisk. 'These results reinforce our confidence in CagriSema, and we continue to study the potential of this combination through the REDEFINE trials.' CagriSema is an investigational product that combines the GLP-1 RA, semaglutide, with an amylin analogue, cagrilintide. The REDEFINE 1 trial found that treatment with CagriSema resulted in greater weight loss of 22.7% at 68 weeks versus 2.3% in the placebo group if all patients adhered to treatment.1* When evaluating the treatment effect regardless of adherence, those treated with CagriSema achieved statistically significant weight loss of 20.4% at 68 weeks versus 3.0% for the placebo group.1** In addition, a supportive secondary analysis showed that half (50.7%) of trial participants with obesity treated with CagriSema reached the threshold for non-obesity (BMI < 30 kg/m2) at the end of treatment, from a mean BMI of 38 kg/m2 at the start of treatment. In the placebo group,10.2% reached that threshold at 68 weeks.1 Select confirmatory secondary endpoints showed that if all participants adhered to treatment 40.4% of those receiving CagriSema achieved a body weight reduction of ≥25%.* Additionally, 23.1% lost ≥30% of their body weight.1* When applying the treatment policy estimand, 34.7% of participants treated with CagriSema achieved ≥25% body-weight reduction and 19.3% achieved ≥30% body-weight reduction.1** In a prespecified analysis of 252 participants, the relative reduction in fat and lean soft-tissue mass from baseline to week 68 was -35.7% (fat mass) and -14.4% (lean soft-tissue mass) for those treated with CagriSema versus –5.7% and –4.3% for the placebo group, respectively.1 "In REDEFINE 1, CagriSema provided weight loss in the highest range of efficacy observed with existing weight loss interventions,' said lead investigator Timothy Garvey, MD, professor of medicine and director of the Diabetes Research Center at the University of Alabama at Birmingham. 'Investigators were allowed some flexibility in dose adjustments to balance efficacy and safety, but regardless of dose adjustments participants lost significant weight. These findings are relatable to clinical practice, where dosing is often adjusted based on individual needs and clinical judgement.' Safety data generated in the REDEFINE 1 and 2 trials were comparable with the GLP-1 RA class. Overall, discontinuation rates due to adverse events were low, with 6% for CagriSema versus 3.7% for placebo in REDEFINE 1 and 8.4% with CagriSema versus 3% with placebo in REDEFINE 2.1,3 In REDEFINE 1, adverse events were mainly gastrointestinal (79.6% in the CagriSema group vs. 39.9% with placebo), including nausea (55% vs. 12.6 %), constipation (30.7% vs. 11.6%), vomiting (26.1% vs. 4.1%) and were mostly transient and mild-to-moderate in severity.1 Results from REDEFINE 2, a phase 3 study that evaluated the efficacy and safety of CagriSema plus lifestyle interventions in adults with obesity and type 2 diabetes (T2D), were also simultaneously presented during a scientific symposium at the ADA's Scientific Sessions and published in NEJM.3 In REDEFINE 2, if all participants adhered to treatment, the estimated mean change in body weight from baseline to week 68 was –15.7% with CagriSema versus –3.1% with placebo.3* When applying the treatment policy estimand, the estimated mean change in body weight from baseline to week 68 was –13.7% with CagriSema versus –3.4% with placebo.3** A greater proportion of participants receiving CagriSema, compared with placebo, reduced their body weight by >5% (83.6% vs. 30.8% of participants), ≥10% (65.6% vs. 10.3%), ≥15% (43.9% vs. 2.4%), and ≥20% (22.9% vs. 0.5%;).3 The safety results from CagriSema in REDEFINE 2 were similar to those reported in REDEFINE 1.3 The REDEFINE clinical programme will continue to assess the efficacy and safety of CagriSema. Most recently, Novo Nordisk initiated the REDEFINE 11 trial with the first patient visit occurring in early June 2025. REDEFINE 11 will explore further weight loss potential and safety of CagriSema 2.4 mg / 2.4 mg through a longer trial duration and other protocol changes compared to REDEFINE 1 and 2. * Based on the trial product estimand; this estimand estimates what the effect would be if all participants adhered to treatment ** Based on the treatment policy estimand: treatment effect regardless of treatment adherence About CagriSemaCagriSema is being investigated by Novo Nordisk as a once-weekly subcutaneous injectable treatment for adults with overweight or obesity (REDEFINE programme) and as a treatment for adults with type 2 diabetes (REIMAGINE programme). CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and semaglutide 2.4 mg. About the REDEFINE clinical trial programmeREDEFINE is a phase 3 clinical development programme with once-weekly subcutaneous CagriSema in obesity. REDEFINE 1 and REDEFINE 2 have enrolled approximately 4,600 adults with overweight or obesity. REDEFINE 1 was a double-blind, placebo-and active-controlled 68-week efficacy and safety phase 3 trial of once-weekly CagriSema, cagrilintide 2.4 mg and semaglutide 2.4 mg versus placebo in 3,417 adults with obesity or overweight with one or more comorbidities and without type 2 diabetes. REDEFINE 2 was a double-blind, randomized, placebo- and controlled 68-week efficacy and safety phase 3 trial of once-weekly CagriSema versus placebo in 1,206 adults with type 2 diabetes and either obesity or overweight. Multiple REDEFINE clinical trials are currently underway including: REDEFINE 3, an event-driven cardiovascular outcomes phase 3 trial; REDEFINE 4 an 84-week head-to-head efficacy and safety phase 3 trial of once-weekly CagriSema versus once-weekly tirzepatide; and REDEFINE 11, a phase 3 trial with longer duration and other protocol changes compared to REDEFINE 1 and 2. About obesity Obesity is a serious chronic, progressive, and complex disease that requires long-term management.4-6 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off.4,6 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.7,8 Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289 abmo@ Liz Skrbkova (US) +1 609 917 0632 lzsk@ Investors: Jacob Martin Wiborg Rode +45 3075 5956 jrde@ Ida Schaap Melvold +45 3077 5649 idmg@ Sina Meyer +45 3079 6656 azey@ Max Ung +45 3077 6414 mxun@ Frederik Taylor Pitter +1 609 613 0568 fptr@ References: Garvey WT, Blüher MD, Contreras CKO, et al. CagriSema in Adults with Overweight or Obesity. New England Journal of Medicine 2025. doi: 10.1056/NEJMoa2502081 A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term. Last Accessed: June 2025. Available at: Davies MJ, Harpreet S, Bajaj MD, et al. CagriSema in Adults with Overweight or Obesity and Type 2 Diabetes. New England Journal of Medicine 2025. Kaplan LM, Golden A, Jinnett K, et al. Perceptions of barriers to effective obesity care: results from the national action study. Obesity. 2018;26(1):61-69. Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Rev. 2017;18(7):715-723. Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22 (Suppl 3):1-203. Centers for Disease Control and Prevention. Adult obesity facts. Last accessed: June 2025. Available at: World Obesity Federation. World Obesity Atlas 2023. Last accessed: June 2025. Available at: Attachment PR250622-ADA-CagriSema
Yahoo
an hour ago
- Yahoo
Edinburgh mum diagnosed with cancer at age 28 gives birth to 'miracle baby'
An Edinburgh mum-of-two who overcame cancer at age 28 is now leading the charge against the disease in Scotland's capital to help save lives. Nikki Milligan was diagnosed with Hodgkin lymphoma, a type of blood cancer, in January 2022. The mum can vividly recall the uncertainty she when doctors at the Western General Hospital broke the news of her diagnosis. READ MORE: Edinburgh locals warn 'we will go to war over parking' if development goes ahead READ MORE: Edinburgh gang war continues as firm with 'links to Mark Richardson' torched In December the year before, a lump appeared near Nikki's collar bone and she suffered symptoms including night sweats. She had an x-ray after blood tests indicated there may be an issue and only hours after the x-ray the GP called her. Nikki said: 'I thought the x-ray results would take around 10 days to come, so when my GP called me back the same day I knew the news wouldn't be good. 'They'd found a tumour on my neck and my chest. I had a biopsy on Christmas Eve, 2021. My daughter was only three at the time and going through Christmas waiting for those final January results was hard.' Nikki lost her long, dark hair to the side effects of treatment. She had six months of chemotherapy in total including two stays in hospital. But on August 18, 2022, Nikki completed her final session. Just months later, Nikki was overjoyed to discover she was pregnant again. Her younger daughter Abbie was born on December 26, 2023. Nikki said: 'I feel so lucky. After treatment for cancer, I didn't even know if I'd be able to have another child but here we are blessed with our Boxing Day baby.' The mum was guest of honour at Cancer Research UK's Race for Life Pretty Muddy Edinburgh. She joined her partner Jason McFarlane and their daughters Zoe, six, and Abbie, one, sounding the starter horn to send 1,500 people on a 5k mud-splattered obstacle course in The Meadows. A total of £160,000 was raised- vital funds which will enable scientists to find new ways to prevent, diagnose and treat cancer- to bring about a world where everybody lives longer, better lives, free from the fear of cancer. Every year around 34,600 people are diagnosed with cancer in Scotland. Nikki, now 31, from Edinburgh picked up a well earned medal after completing Pretty Muddy with Claire Wight, a close friend from their school days together at Tynecastle High School. Nikki said: 'I am incredibly grateful to be here to raise my two girls. It's hard to put in to words exactly how it feels to be healthy and surrounded by love. "This summer will mark three years of me being in remission from cancer. I will forever be thankful to my family for their unwavering support and to the NHS for getting me better. 'I'm proud to be able to help others. I want to support research for people going through cancer right now and to help find better treatments for my daughters' generation.' Cancer Research UK's Race for Life, in partnership with headline sponsor Standard Life, part of Phoenix Group, is an inspiring series of 3k, 5k, 10k, Pretty Muddy and Pretty Muddy Kids events which raise millions of pounds every year to help beat cancer by funding crucial research. Now organisers are sending a heartfelt message of thanks to everyone who put their best feet forward as well as their supporters. And they're appealing for people to make every step count by paying in sponsorship money as soon as possible. Since it began in 1994, more than 10 million people have taken part in Race for Life, contributing millions of pounds towards life-saving research. Race for Life events which take place across the country are open to all ages and abilities. It includes events everywhere from Aberdeen to Ayr, Falkirk to Fife, Edinburgh, Dundee, Stirling and Inverness. Join Edinburgh Live's Whatsapp Community here and get the latest news sent straight to your messages.
Yahoo
2 hours ago
- Yahoo
'Devastation' following death of David 'Syd' Lawrence
Friends and colleagues have spoken of their "devastation" following the death of former cricketer David "Syd" Lawrence MBE. Lawrence, the first British-born black cricketer to represent England, was diagnosed with motor neurone disease (MND) in 2024. Advertisement Earlier this month, the 61-year-old, from Gloucester, said he was "incredibly proud" to be appointed an MBE in the King's Birthday Honours in recognition of his services to cricket. Mark Alleyne, head coach at Gloucestershire County Cricket Club (GCCC) said: "When you come to moments like this, as sad as it is, at least we know one thing that he lived a very full and colourful life." MND is a rare, degenerative condition that affects the brain and nerves. There is no cure. Peter Matthews is the chair of GCCC [BBC] Peter Matthews, chair of GCCC, said a minute's silence was held at the start of Sunday's home match against Derbyshire to commemorate the "desperately sad" passing of Lawrence. Advertisement "Because of the nature of [MND], you know it's going to happen at some stage, but it's still a shock," Mr Matthews said. He credited Lawrence's "wonderful legacy" both on and off the field. "He always gave everything. He was a brilliant cricketer. "He broke down barriers, he was so obviously himself, he exuded confidence, but obviously he was a really genuine man alongside that confidence. "He was a wonderful president. While of course his body was failing him, the tragedy in some respects of motor neurone disease is that the brain doesn't fail you, so he was always there to give ideas and provide insight to me as a relatively new chair," Mr Matthews added. Neil Priscott described Lawrence as an "icon" [BBC] Neil Priscott, chief executive officer of GCCC, described Lawrence's work with the club as "transformational". Advertisement "He brought in life, that energy and that infectious spirit. He brought that in his presidency in day one. "He wanted us to reach out to communities far and wide, push ourselves, do more, find the next generation of talent and that infectiousness sort of carried everyone with him. "Syd's been an icon for this club on the field and off it. "We absolutely want to continue that legacy and do that in his honour." David Graveney was Lawrence's first captain [BBC] David Graveney, vice chairman of GCCC, was Lawrence's first captain. At the start of Lawrence's career, Mr Graveney watched him develop from a county bowler to an international star. Advertisement "His legacy to the game is in many, many forms. "The fact he was the first English-born black person to play for England was a thing he was very proud of and he was the first black president of the cricket club - another thing he was really proud of. "He shows that actually it doesn't matter what your background is, if you apply yourself then the sky's the limit," Mr Graveney said. Andy Brassington first met Lawrence when he was 16 years old [BBC] Andy Brassington is a former cricketer and friend of Lawrence. He visited Lawrence on Saturday and was with him just an hour before he passed away. "It's been a terrible illness. He's taken it head on, like he does with everything Advertisement "To see him in the state he was in then, there was a lot of relief when they called me to say he'd passed on because it wasn't a good place to be for him. "He's probably in a better place now, that's for sure," Mr Brassington said. He added that the cricketing world will look after Lawrence's wife and son and will carry on his legacy. "He's been brave, he's a very proud man, his appearance is everything to him, yet he put himself in the shop window to show people how this disease can tear your body apart. "He's given hope to people. We all need heroes, we all need idols and Syd was there for so many people. Advertisement "I always say time is the greatest gift you can give anybody and Syd gave a lot of people a lot of time," said Mr Brassington. Lawrence was a former fast bowler for England and Gloucestershire [Getty Images] Lawrence established himself as a "club icon" throughout his 16-year career, becoming known for his "thunderous run-up, fearless fast bowling and ever-present energy", his family said in a statement. He played five Test Matches for England and took 625 wickets in 280 matches before his cricket career was cut short by injury in 1992. In 2022, Lawrence was appointed president of GCCC - a position he held up until his death. Throughout his final year, Lawrence appeared at many charity events to raise awareness of MND. Advertisement Follow BBC Gloucestershire on Facebook, X and Instagram. Send your story ideas to us on email or via WhatsApp on 0800 313 4630. More on this story Related Internet Links
